慢性淋巴细胞性白血病-话题@MedSci - 梅斯（MedSci）

#慢性淋巴细胞性白血病#

12篇内容 | 1268人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1391425, encodeId=c85a1391425be, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=Cell Death Differ：非典型NF-κB信号转导通路影响慢性淋巴细胞性白血病的耐药性, objectType=article, longId=206400, objectId=1f6b206400f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6b206400f1, replyNumber=0, likeNumber=62, createdTime=2021-01-31, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6b206400f1, moduleTitle=Cell Death Differ：非典型NF-κB信号转导通路影响慢性淋巴细胞性白血病的耐药性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1f6b206400f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持, objectType=article, longId=203281, objectId=a9322032812e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9322032812e, replyNumber=0, likeNumber=72, createdTime=2020-11-13, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9322032812e, moduleTitle=Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a9322032812e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391423, encodeId=e404139142364, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, objectType=article, longId=200404, objectId=d860200404a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d860200404a6, replyNumber=0, likeNumber=78, createdTime=2020-09-09, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d860200404a6, moduleTitle=FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d860200404a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391422, encodeId=c5dd13914227f, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, objectType=article, longId=193606, objectId=c7931936061f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7931936061f, replyNumber=0, likeNumber=52, createdTime=2020-05-08, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7931936061f, moduleTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c7931936061f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391421, encodeId=c00d1391421b1, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=CLIN CANCER RES：Venetoclax单药治疗慢性淋巴细胞性白血病安全性分析, objectType=article, longId=149134, objectId=972614913424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=972614913424, replyNumber=0, likeNumber=74, createdTime=2018-09-21, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=972614913424, moduleTitle=CLIN CANCER RES：Venetoclax单药治疗慢性淋巴细胞性白血病安全性分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=972614913424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391420, encodeId=8616139142009, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=Blood：阻断PD-1通路可能阻止慢性淋巴细胞性白血病向急性淋巴细胞性白血病转化, objectType=article, longId=104075, objectId=1e541040e532, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e541040e532, replyNumber=0, likeNumber=0, createdTime=2017-07-01, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e541040e532, moduleTitle=Blood：阻断PD-1通路可能阻止慢性淋巴细胞性白血病向急性淋巴细胞性白血病转化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1e541040e532)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391419, encodeId=7800139141935, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=CLIN PHARMACOKINET：Venetoclax对复发性或难治性慢性淋巴细胞性白血病的疗效和安全性如何？, objectType=article, longId=100534, objectId=b13c10053405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b13c10053405, replyNumber=0, likeNumber=0, createdTime=2017-06-04, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b13c10053405, moduleTitle=CLIN PHARMACOKINET：Venetoclax对复发性或难治性慢性淋巴细胞性白血病的疗效和安全性如何？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b13c10053405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391418, encodeId=7a0e139141820, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=Blood：治疗慢性淋巴细胞性白血病，新一代布鲁顿氏酪氨酸激酶抑制剂更少副作用, objectType=article, longId=99488, objectId=59bc994889c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59bc994889c, replyNumber=0, likeNumber=74, createdTime=2017-05-25, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59bc994889c, moduleTitle=Blood：治疗慢性淋巴细胞性白血病，新一代布鲁顿氏酪氨酸激酶抑制剂更少副作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=59bc994889c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391417, encodeId=05b7139141ee1, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=CLIN CANCER RES：依鲁替尼联合利妥昔单抗治疗高风险慢性淋巴细胞性白血病, objectType=article, longId=97949, objectId=75999e94942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75999e94942, replyNumber=0, likeNumber=104, createdTime=2017-05-07, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75999e94942, moduleTitle=CLIN CANCER RES：依鲁替尼联合利妥昔单抗治疗高风险慢性淋巴细胞性白血病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=75999e94942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391416, encodeId=ad7f139141600, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=JCO：慢性淋巴细胞性白血病患者口服靶向治疗药物的经济负担研究, objectType=article, longId=83024, objectId=ed04830241f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed04830241f, replyNumber=0, likeNumber=65, createdTime=2016-11-26, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed04830241f, moduleTitle=JCO：慢性淋巴细胞性白血病患者口服靶向治疗药物的经济负担研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ed04830241f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391415, encodeId=218f13914158d, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=NEJM：venetoclax治疗复发慢性淋巴细胞性白血病初见成效, objectType=article, longId=60349, objectId=43666034930, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43666034930, replyNumber=0, likeNumber=66, createdTime=2015-12-08, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43666034930, moduleTitle=NEJM：venetoclax治疗复发慢性淋巴细胞性白血病初见成效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43666034930)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1391414, encodeId=6fbd13914140e, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, objectTitle=Leukemia：慢性淋巴细胞性白血病患者的潜在新疗法, objectType=article, longId=33923, objectId=ef21339236c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef21339236c, replyNumber=0, likeNumber=70, createdTime=2014-05-01, rootId=0, userName=ms5439512287675881, userId=1d8d2500080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef21339236c, moduleTitle=Leukemia：慢性淋巴细胞性白血病患者的潜在新疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ef21339236c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

慢性淋巴细胞性白血病

2020-05-29

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

Cell Death Differ：非典型NF-κB信号转导通路影响慢性淋巴细胞性白血病的耐药性

2021-01-31

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持

2020-11-13

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病

2020-09-09

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

2020-05-08

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

CLIN CANCER RES：Venetoclax单药治疗慢性淋巴细胞性白血病安全性分析

2018-09-21

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

Blood：阻断PD-1通路可能阻止慢性淋巴细胞性白血病向急性淋巴细胞性白血病转化

2017-07-01

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

CLIN PHARMACOKINET：Venetoclax对复发性或难治性慢性淋巴细胞性白血病的疗效和安全性如何？

2017-06-04

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

Blood：治疗慢性淋巴细胞性白血病，新一代布鲁顿氏酪氨酸激酶抑制剂更少副作用

2017-05-25

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

CLIN CANCER RES：依鲁替尼联合利妥昔单抗治疗高风险慢性淋巴细胞性白血病

2017-05-07

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

JCO：慢性淋巴细胞性白血病患者口服靶向治疗药物的经济负担研究

2016-11-26

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

NEJM：venetoclax治疗复发慢性淋巴细胞性白血病初见成效

2015-12-08

ms5439512287675881 (审核中...)

前往app查看评论内容

#慢性淋巴细胞性白血病#

Leukemia：慢性淋巴细胞性白血病患者的潜在新疗法

2014-05-01

科室
- - 订阅+
  - 更多科室
工具
服务